Together, these findings highlight MTD’s ability to detect cognitive change in a large group of predominantly (94%) CU individuals that is associated with greater levels of amyloid and tau burden, consistent with the biological diagnosis of AD, as well as hippocampal and WMH volumes, together which supports MTD’s criterion validity. Here, MAPT is linked to Alzheimer disease.